

# Alice B Gottlieb

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3797640/publications.pdf>

Version: 2024-02-01

180  
papers

12,719  
citations

50273

46  
h-index

24978

109  
g-index

187  
all docs

187  
docs citations

187  
times ranked

8163  
citing authors

#	ARTICLE	IF	CITATIONS
1	Etanercept as Monotherapy in Patients with Psoriasis. <i>New England Journal of Medicine</i> , 2003, 349, 2014-2022.	27.0	1,114
2	Group for Research and Assessment of Psoriasis and Psoriatic Arthritis 2015 Treatment Recommendations for Psoriatic Arthritis. <i>Arthritis and Rheumatology</i> , 2016, 68, 1060-1071.	5.6	726
3	Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial. <i>Lancet, The</i> , 2015, 386, 1137-1146.	13.7	722
4	Psoriasis. <i>Nature Reviews Disease Primers</i> , 2016, 2, 16082.	30.5	585
5	Ustekinumab, a human interleukin 12/23 monoclonal antibody, for psoriatic arthritis: randomised, double-blind, placebo-controlled, crossover trial. <i>Lancet, The</i> , 2009, 373, 633-640.	13.7	545
6	Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics. <i>Journal of the American Academy of Dermatology</i> , 2019, 80, 1029-1072.	1.2	542
7	Two Phase 3 Trials of Adalimumab for Hidradenitis Suppurativa. <i>New England Journal of Medicine</i> , 2016, 375, 422-434.	27.0	530
8	Infliximab induction therapy for patients with severe plaque-type psoriasis: A randomized, double-blind, placebo-controlled trial. <i>Journal of the American Academy of Dermatology</i> , 2004, 51, 534-542.	1.2	528
9	Guidelines of care for the management of psoriasis and psoriatic arthritis. <i>Journal of the American Academy of Dermatology</i> , 2008, 58, 851-864.	1.2	456
10	Prevalence of psoriatic arthritis in patients with psoriasis: A systematic review and meta-analysis of observational and clinical studies. <i>Journal of the American Academy of Dermatology</i> , 2019, 80, 251-265.e19.	1.2	362
11	Ixekizumab for the treatment of patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors: results from the 24-week randomised, double-blind, placebo-controlled period of the SPIRIT-P2 phase 3 trial. <i>Lancet, The</i> , 2017, 389, 2317-2327.	13.7	316
12	Guidelines of care for the management of psoriasis and psoriatic arthritis. <i>Journal of the American Academy of Dermatology</i> , 2010, 62, 114-135.	1.2	311
13	Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with awareness and attention to comorbidities. <i>Journal of the American Academy of Dermatology</i> , 2019, 80, 1073-1113.	1.2	281
14	Safety Surveillance for Ustekinumab and Other Psoriasis Treatments From the Psoriasis Longitudinal Assessment and Registry (PSOLAR). <i>Journal of Drugs in Dermatology</i> , 2015, 14, 706-14.	0.8	214
15	Psoriasis comorbidities. <i>Journal of Dermatological Treatment</i> , 2008, 19, 5-21.	2.2	210
16	Guselkumab in biologic-naïve patients with active psoriatic arthritis (DISCOVER-2): a double-blind, randomised, placebo-controlled phase 3 trial. <i>Lancet, The</i> , 2020, 395, 1126-1136.	13.7	206
17	Efficacy and safety of abatacept, a T-cell modulator, in a randomised, double-blind, placebo-controlled, phase III study in psoriatic arthritis. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 1550-1558.	0.9	184
18	Secukinumab versus adalimumab for treatment of active psoriatic arthritis (EXCEED): a double-blind, parallel-group, randomised, active-controlled, phase 3b trial. <i>Lancet, The</i> , 2020, 395, 1496-1505.	13.7	178

#	ARTICLE	IF	CITATIONS
19	Dual neutralization of both interleukin 17A and interleukin 17F with bimekizumab in patients with psoriasis: Results from BE ABLE 1, a 12-week randomized, double-blinded, placebo-controlled phase 2b trial. <i>Journal of the American Academy of Dermatology</i> , 2018, 79, 277-286.e10.	1.2	163
20	Comorbidities in Patients with Psoriasis. <i>American Journal of Medicine</i> , 2009, 122, 1150.e1-1150.e9.	1.5	161
21	Efficacy and safety of guselkumab in patients with active psoriatic arthritis: a randomised, double-blind, placebo-controlled, phase 2 study. <i>Lancet, The</i> , 2018, 391, 2213-2224.	13.7	159
22	Consensus on a core set of domains for psoriatic arthritis. <i>Journal of Rheumatology</i> , 2007, 34, 1167-70.	2.0	155
23	Ruxolitinib cream for treatment of vitiligo: a randomised, controlled, phase 2 trial. <i>Lancet, The</i> , 2020, 396, 110-120.	13.7	148
24	Treatment of vitiligo with the topical Janus kinase inhibitor ruxolitinib. <i>Journal of the American Academy of Dermatology</i> , 2017, 76, 1054-1060.e1.	1.2	147
25	From the Medical Board of the National Psoriasis Foundation: Treatment targets for plaque psoriasis. <i>Journal of the American Academy of Dermatology</i> , 2017, 76, 290-298.	1.2	137
26	Efficacy and safety of ustekinumab in psoriatic arthritis patients with peripheral arthritis and physician-reported spondylitis: post-hoc analyses from two phase III, multicentre, double-blind, placebo-controlled studies (PSUMMIT-1/PSUMMIT-2). <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 1984-1988.	0.9	131
27	Certolizumab pegol for the treatment of chronic plaque psoriasis: Results through 48 weeks from 2 phase 3, multicenter, randomized, double-blinded, placebo-controlled studies (CIMPASI-1 and Tj ETQq1 1 0.784314.2gBT /Overlock 10		
28	Joint American Academy of Dermatology and National Psoriasis Foundation guidelines of care for the management and treatment of psoriasis in pediatric patients. <i>Journal of the American Academy of Dermatology</i> , 2020, 82, 161-201.	1.2	129
29	Secukinumab shows significant efficacy in palmoplantar psoriasis: Results from GESTURE, a randomized controlled trial. <i>Journal of the American Academy of Dermatology</i> , 2017, 76, 70-80.	1.2	128
30	Bimekizumab in patients with active psoriatic arthritis: results from a 48-week, randomised, double-blind, placebo-controlled, dose-ranging phase 2b trial. <i>Lancet, The</i> , 2020, 395, 427-440.	13.7	122
31	Secukinumab sustains improvement in signs and symptoms of psoriatic arthritis: 2 year results from the phase 3 FUTURE 2 study. <i>Rheumatology</i> , 2017, 56, 1993-2003.	1.9	121
32	Research gaps in psoriasis: Opportunities for future studies. <i>Journal of the American Academy of Dermatology</i> , 2014, 70, 146-167.	1.2	101
33	A phase 1, double-blind, placebo-controlled study evaluating single subcutaneous administrations of a human interleukin-12/23 monoclonal antibody in subjects with plaque psoriasis. <i>Current Medical Research and Opinion</i> , 2007, 23, 1081-1092.	1.9	98
34	Maintenance of Clinical Efficacy and Radiographic Benefit Through Two Years of Ustekinumab Therapy in Patients With Active Psoriatic Arthritis: Results From a Randomized, Placebo-Controlled Phase III Trial. <i>Arthritis Care and Research</i> , 2015, 67, 1739-1749.	3.4	87
35	Clinical characteristics of psoriatic arthritis and psoriasis in dermatologists' offices. <i>Journal of Dermatological Treatment</i> , 2006, 17, 279-287.	2.2	72
36	Group for Research and Assessment of Psoriasis and Psoriatic Arthritis/Outcome Measures in Rheumatology Consensus-Based Recommendations and Research Agenda for Use of Composite Measures and Treatment Targets in Psoriatic Arthritis. <i>Arthritis and Rheumatology</i> , 2018, 70, 345-355.	5.6	72

#	ARTICLE	IF	CITATIONS
37	Management of psoriasis in patients with inflammatory bowel disease: From the Medical Board of the National Psoriasis Foundation. <i>Journal of the American Academy of Dermatology</i> , 2018, 78, 383-394.	1.2	69
38	Psoriasis in the elderly: From the Medical Board of the National Psoriasis Foundation. <i>Journal of the American Academy of Dermatology</i> , 2011, 65, 537-545.	1.2	65
39	Clinical Goals and Barriers to Effective Psoriasis Care. <i>Dermatology and Therapy</i> , 2019, 9, 5-18.	3.0	63
40	Secukinumab in the treatment of moderate to severe hidradenitis suppurativa: Results of an open-label trial. <i>Journal of the American Academy of Dermatology</i> , 2020, 82, 1524-1526.	1.2	62
41	Specific targeting of interleukin-23p19 as effective treatment for psoriasis. <i>Journal of the American Academy of Dermatology</i> , 2014, 70, 555-561.	1.2	60
42	Safety observations in 12095 patients with psoriasis enrolled in an international registry (PSOLAR): experience with infliximab and other systemic and biologic therapies. <i>Journal of Drugs in Dermatology</i> , 2014, 13, 1441-8.	0.8	60
43	A Phase II Open-Label Study of Bermekimab in Patients with Hidradenitis Suppurativa Shows Resolution of Inflammatory Lesions and Pain. <i>Journal of Investigative Dermatology</i> , 2020, 140, 1538-1545.e2.	0.7	59
44	The Challenge of Managing Psoriasis: Unmet Medical Needs and Stakeholder Perspectives. <i>American Health and Drug Benefits</i> , 2016, 9, 504-513.	0.5	58
45	Psoriasis and the metabolic syndrome. <i>Journal of Drugs in Dermatology</i> , 2008, 7, 563-72.	0.8	54
46	Incidence and prevalence of psoriatic arthritis in Denmark: a nationwide register linkage study. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 1591-1597.	0.9	52
47	Psoriatic arthritis for dermatologists. <i>Journal of Dermatological Treatment</i> , 2020, 31, 662-679.	2.2	52
48	Bimekizumab for patients with moderate to severe plaque psoriasis: 60-week results from BE ABLE 2, a randomized, double-blinded, placebo-controlled, phase 2b extension study. <i>Journal of the American Academy of Dermatology</i> , 2020, 83, 1367-1374.	1.2	48
49	Efficacy and Safety of Guselkumab, an Interleukin-23p19-Specific Monoclonal Antibody, Through One Year in Biologic-Naive Patients With Psoriatic Arthritis. <i>Arthritis and Rheumatology</i> , 2021, 73, 604-616.	5.6	48
50	Safety of Ixekizumab in Patients With Psoriatic Arthritis: Results From a Pooled Analysis of Three Clinical Trials. <i>Arthritis Care and Research</i> , 2019, 71, 367-378.	3.4	47
51	Management of psoriatic arthritis from the view of the dermatologist. <i>Nature Reviews Rheumatology</i> , 2011, 7, 588-598.	8.0	45
52	The International Dermatology Outcome Measures Group: Formation of patient-centered outcome measures in dermatology. <i>Journal of the American Academy of Dermatology</i> , 2015, 72, 345-348.	1.2	44
53	Clinical considerations for the management of psoriasis in women. <i>International Journal of Women's Dermatology</i> , 2019, 5, 141-150.	2.0	44
54	Use of etanercept for psoriatic arthritis in the dermatology clinic: The Experience Diagnosing, Understanding Care, and Treatment with Etanercept (EDUCATE) study. <i>Journal of Dermatological Treatment</i> , 2006, 17, 343-352.	2.2	43

#	ARTICLE	IF	CITATIONS
55	Efficacy and safety of tildrakizumab in patients with active psoriatic arthritis: results of a randomised, double-blind, placebo-controlled, multiple-dose, 52-week phase IIb study. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 1147-1157.	0.9	43
56	Identifying a Core Domain Set to Assess Psoriasis in Clinical Trials. <i>JAMA Dermatology</i> , 2018, 154, 1137.	4.1	41
57	Axial psoriatic arthritis: An update for dermatologists. <i>Journal of the American Academy of Dermatology</i> , 2021, 84, 92-101.	1.2	41
58	Long-term Efficacy and Safety of Guselkumab, a Monoclonal Antibody Specific to the p19 Subunit of Interleukin-23, Through Two Years: Results From a Phase III, Randomized, Double-blind, Placebo-controlled Study Conducted in Biologic-naïve Patients With Active Psoriatic Arthritis. <i>Arthritis and Rheumatology</i> , 2022, 74, 475-485.	5.6	41
59	Secukinumab Improves Physical Function in Subjects With Plaque Psoriasis and Psoriatic Arthritis: Results from Two Randomized, Phase 3 Trials. <i>Journal of Drugs in Dermatology</i> , 2015, 14, 821-33.	0.8	40
60	Impact of ixekizumab on psoriasis itch severity and other psoriasis symptoms: Results from 3 phase III psoriasis clinical trials. <i>Journal of the American Academy of Dermatology</i> , 2016, 75, 1156-1161.	1.2	39
61	Ustekinumab in the treatment of psoriatic arthritis: latest findings and clinical potential. <i>Therapeutic Advances in Musculoskeletal Disease</i> , 2013, 5, 277-285.	2.7	38
62	CCL20 and IL22 Messenger RNA Expression After Adalimumab vs Methotrexate Treatment of Psoriasis. <i>JAMA Dermatology</i> , 2015, 151, 837.	4.1	38
63	Protocol for the development of a core domain set for hidradenitis suppurativa trial outcomes. <i>BMJ Open</i> , 2017, 7, e014733.	1.9	37
64	Treatment of coexistent psoriasis and lupus erythematosus. <i>Journal of the American Academy of Dermatology</i> , 2015, 72, 253-260.	1.2	36
65	Tumor Necrosis Factor Blockade: Mechanism of Action. <i>Journal of Investigative Dermatology Symposium Proceedings</i> , 2007, 12, 1-4.	0.8	35
66	Secukinumab improves patient-reported psoriasis symptoms of itching, pain, and scaling: results of two phase 3, randomized, placebo-controlled clinical trials. <i>International Journal of Dermatology</i> , 2016, 55, 401-407.	1.0	34
67	4-year results from the RAPID-PsA phase 3 randomised placebo-controlled trial of certolizumab pegol in psoriatic arthritis. <i>RMD Open</i> , 2018, 4, e000582.	3.8	34
68	Long-term Safety of Secukinumab Over Five Years in Patients with Moderate-to-severe Plaque Psoriasis, Psoriatic Arthritis and Ankylosing Spondylitis: Update on Integrated Pooled Clinical Trial and Post-marketing Surveillance Data. <i>Acta Dermato-Venereologica</i> , 2022, 102, adv00698.	1.3	34
69	High-dose ustekinumab for the treatment of severe, recalcitrant pyoderma gangrenosum. <i>Dermatologic Therapy</i> , 2016, 29, 482-483.	1.7	33
70	Importance of light in the treatment of vitiligo with JAK-inhibitors. <i>Journal of Dermatological Treatment</i> , 2018, 29, 98-99.	2.2	30
71	Axial Involvement in Psoriatic Arthritis cohort (AXIS): the protocol of a joint project of the Assessment of SpondyloArthritis international Society (ASAS) and the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA). <i>Therapeutic Advances in Musculoskeletal Disease</i> , 2021, 13, 1759720X2110579.	2.7	30
72	Deucravacitinib in Moderate to Severe Psoriasis: Clinical and Quality-of-Life Outcomes in a Phase 2 Trial. <i>Dermatology and Therapy</i> , 2022, 12, 495-510.	3.0	30

#	ARTICLE	IF	CITATIONS
73	The contribution of joint and skin improvements to the health-related quality of life of patients with psoriatic arthritis: a post hoc analysis of two randomised controlled studies. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 1215-1219.	0.9	29
74	Secukinumab sustains early patient-reported outcome benefits through 1Âyear: Results from 2 phase III randomized placebo-controlled clinical trials comparing secukinumab with etanercept. <i>Journal of the American Academy of Dermatology</i> , 2017, 76, 655-661.	1.2	28
75	Ustekinumab Treatment and Improvement of Physical Function and HealthâRelated Quality of Life in Patients With Psoriatic Arthritis. <i>Arthritis Care and Research</i> , 2016, 68, 1812-1822.	3.4	27
76	Ixekizumab improves patient-reported outcomes up to 52 weeks in bDMARD-naïve patients with active psoriatic arthritis (SPIRIT-P1). <i>Rheumatology</i> , 2018, 57, 1777-1788.	1.9	27
77	Clinical Disease Measures in Generalized Pustular Psoriasis. <i>American Journal of Clinical Dermatology</i> , 2022, 23, 39-50.	6.7	25
78	Psoriasis Outcome Measures: A Report from the GRAPPA 2012 Annual Meeting. <i>Journal of Rheumatology</i> , 2013, 40, 1428-1433.	2.0	22
79	The Development of a Patient-Reported Outcome Measure for Assessment of Genital Psoriasis Symptoms: The Genital Psoriasis Symptoms Scale (GPSS). <i>Dermatology and Therapy</i> , 2018, 8, 45-56.	3.0	21
80	Probiotics for oral and vulvovaginal candidiasis: A review. <i>Dermatologic Therapy</i> , 2019, 32, e12970.	1.7	21
81	Validation and response to treatment of a pruritus self-assessment tool in patients with moderate to severe psoriasis. <i>Journal of the American Academy of Dermatology</i> , 2010, 63, 580-586.	1.2	20
82	First-In-Human, Phase 1, Randomized, Dose-Escalation Trial with Recombinant AntiâIL-20 Monoclonal Antibody in Patients with Psoriasis. <i>PLoS ONE</i> , 2015, 10, e0134703.	2.5	20
83	Assessing clinical response and defining minimal disease activity in plaque psoriasis with the Physician Global Assessment and body surface area (PGAâBSA) composite tool: An analysis of apremilast phase 3 ESTEEM data. <i>Journal of the American Academy of Dermatology</i> , 2017, 77, 1178-1180.	1.2	20
84	Pooled Safety Results Through 1 Year of 2 Phase III Trials of Guselkumab in Patients With Psoriatic Arthritis. <i>Journal of Rheumatology</i> , 2021, 48, 1815-1823.	2.0	20
85	Serious infections in patients with self-reported psoriatic arthritis from the Psoriasis Longitudinal Assessment and Registry (PSOLAR) treated with biologics. <i>BMC Rheumatology</i> , 2019, 3, 52.	1.6	19
86	Comparison of Different Remission and Low Disease Definitions in Psoriatic Arthritis and Evaluation of Their Prognostic Value. <i>Journal of Rheumatology</i> , 2019, 46, 160-165.	2.0	19
87	The International Dermatology Outcome Measures Initiative as Applied to Psoriatic Disease Outcomes: A Report from the GRAPPA 2013 Meeting. <i>Journal of Rheumatology</i> , 2014, 41, 1227-1229.	2.0	18
88	Secukinumab for treating plaque psoriasis. <i>Expert Opinion on Biological Therapy</i> , 2016, 16, 119-128.	3.1	18
89	Evaluation of sPGAâBSA as an Outcome Measure and Treatment Target for ClinicalâPractice. <i>Journal of Investigative Dermatology</i> , 2018, 138, 1955-1961.	0.7	18
90	Bimekizumab for the treatment of psoriatic disease. <i>Expert Opinion on Biological Therapy</i> , 2018, 18, 1193-1197.	3.1	16

#	ARTICLE	IF	CITATIONS
91	Achieving consensus on patient-reported outcome measures in clinical practice for inflammatory skin disorders. <i>Journal of the American Academy of Dermatology</i> , 2023, 88, 86-93.	1.2	16
92	Efficacy of ruxolitinib cream in vitiligo by patient characteristics and affected body areas: Descriptive subgroup analyses from a phase 2, randomized, double-blind trial. <i>Journal of the American Academy of Dermatology</i> , 2022, 86, 1398-1401.	1.2	16
93	Consistency of Infliximab Response across Subgroups of Patients with Psoriasis: Integrated Results from Randomized Clinical Trials. <i>Psoriasis Forum</i> , 2007, 13a, 21-27.	0.1	15
94	Malignancy Rates in Brodalumab Clinical Studies for Psoriasis. <i>American Journal of Clinical Dermatology</i> , 2020, 21, 421-430.	6.7	15
95	Safety and Efficacy of Therapies for Skin Symptoms of Psoriasis in Patients with Psoriatic Arthritis: A Systematic Review. <i>Journal of Rheumatology</i> , 2014, 41, 2301-2305.	2.0	14
96	The Development of the Genital Psoriasis Sexual Frequency Questionnaire (GenPs-SFQ) to Assess the Impact of Genital Psoriasis on Sexual Health. <i>Dermatology and Therapy</i> , 2018, 8, 33-44.	3.0	14
97	Secukinumab Efficacy in Psoriatic Arthritis. <i>Journal of Clinical Rheumatology</i> , 2021, 27, 239-247.	0.9	14
98	Psoriatic Arthritis for the Dermatologist. <i>Dermatologic Clinics</i> , 2015, 33, 127-148.	1.7	13
99	Tildrakizumab efficacy and safety are not altered by metabolic syndrome status in patients with psoriasis: Post hoc analysis of 2 phase 3 randomized controlled studies (reSURFACE 1 and reSURFACE 2). <i>Journal of Rheumatology</i> , 2021, 48, 1784-1791.	2.7	13
100	Psoriatic Eye Manifestations. <i>Psoriasis Forum</i> , 2011, 17a, 169-179.	0.1	11
101	Anti IL-17 flared psoriasis in a patient on secukinumab. <i>Dermatologic Therapy</i> , 2017, 30, e12505.	1.7	11
102	Association Between Enthesitis and Health-related Quality of Life in Psoriatic Arthritis in Biologic-naive Patients from 2 Phase III Ustekinumab Trials. <i>Journal of Rheumatology</i> , 2019, 46, 1458-1461.	2.0	11
103	Composite Measures of Disease Activity in Psoriatic Arthritis: Comparative Instrument Performance Based on the Efficacy of Guselkumab in an Interventional Phase II Trial. <i>Arthritis Care and Research</i> , 2020, 72, 1579-1588.	3.4	11
104	Tildrakizumab efficacy, drug survival, and safety are comparable in patients with psoriasis with and without metabolic syndrome: Long-term results from 2 phase 3 randomized controlled studies (reSURFACE 1 and reSURFACE 2). <i>Journal of the American Academy of Dermatology</i> , 2021, 84, 398-407.	1.2	11
105	Insights on methotrexate in psoriatic disease. <i>Clinical Immunology</i> , 2016, 172, 61-64.	3.2	10
106	Demography, baseline disease characteristics, and treatment history of psoriasis patients with self-reported psoriatic arthritis enrolled in the PSOLAR registry. <i>BMC Rheumatology</i> , 2018, 2, 29.	1.6	10
107	Are Your Patients Satisfied? A Systematic Review of Treatment Satisfaction Measures in Psoriasis. <i>Dermatology</i> , 2018, 234, 157-165.	2.1	10
108	Defining Outcome Measures for Psoriasis: The IDEOM Report from the GRAPPA 2016 Annual Meeting. <i>Journal of Rheumatology</i> , 2017, 44, 701-702.	2.0	9

#	ARTICLE	IF	CITATIONS
109	Psoriasis Trends and Practice Gaps. <i>Dermatologic Clinics</i> , 2016, 34, 235-242.	1.7	8
110	International Dermatology Outcome Measures Initiative as Applied to Psoriatic Disease Outcomes: An Update. <i>Journal of Rheumatology</i> , 2016, 43, 959-960.	2.0	8
111	Exploration of the Product of the 5-Point Investigator's Global Assessment and Body Surface Area (IGA A—BSA) as a Practical Minimal Disease Activity Goal in Patients with Moderate-to-Severe Psoriasis. <i>Dermatology</i> , 2019, 235, 348-354.	2.1	8
112	Report of the Skin Research Working Groups From the GRAPPA 2020 Annual Meeting. <i>Journal of Rheumatology</i> , 2021, , jrheum.201668.	2.0	8
113	Translating psoriasis guidelines into practice: Important gaps revealed. <i>Journal of the American Academy of Dermatology</i> , 2016, 74, 544-551.	1.2	7
114	A provider global assessment quality measure for clinical practice for inflammatory skin disorders. <i>Journal of the American Academy of Dermatology</i> , 2019, 80, 823-828.	1.2	7
115	Indirect comparisons of ixekizumab versus three interleukin-23 p19 inhibitors in patients with moderate-to-severe plaque psoriasis " efficacy findings up to week 12. <i>Journal of Dermatological Treatment</i> , 2022, 33, 54-61.	2.2	7
116	Clinical implications and predictive values of early PASI responses to tildrakizumab in patients with moderate-to-severe plaque psoriasis. <i>Journal of Dermatological Treatment</i> , 2022, 33, 1670-1675.	2.2	7
117	Improving health literacy and treatment understanding of hidradenitis suppurativa using group educational interventions. <i>Journal of Dermatological Treatment</i> , 2019, 30, 708-713.	2.2	6
118	Treatment of Medicare Patients with Moderate-to-Severe Psoriasis who Cannot Afford Biologics or Apremilast. <i>American Journal of Clinical Dermatology</i> , 2020, 21, 109-117.	6.7	6
119	Clinical efficacy and safety of secukinumab in patients with psoriasis and comorbidities: pooled analysis of 4 phase 3 clinical trials. <i>Journal of Dermatological Treatment</i> , 2022, 33, 1482-1490.	2.2	6
120	Development and Content Validation of the Psoriasis Symptoms and Impacts Measure (P-SIM) for Assessment of Plaque Psoriasis. <i>Dermatology and Therapy</i> , 2020, 10, 1255-1272.	3.0	6
121	Dupilumab in HIV-positive patients: A case series report of 4 patients. <i>JAAD Case Reports</i> , 2020, 6, 1356-1359.	0.8	6
122	Investigator and Patient Global Assessment Measures for Psoriasis Clinical Trials: A Systematic Review on Measurement Properties from the International Dermatology Outcome Measures (IDEOM) Initiative. <i>American Journal of Clinical Dermatology</i> , 2020, 21, 323-338.	6.7	6
123	Examination of Treatment Satisfaction Instruments in Psoriasis: 2017 Results from the Psoriasis Working Group of the International Dermatology Outcome Measures (IDEOM). <i>Dermatology</i> , 2021, 237, 151-157.	2.1	6
124	A clinical perspective on risk factors and signs of subclinical and early psoriatic arthritis among patients with psoriasis. <i>Journal of Dermatological Treatment</i> , 2022, 33, 1907-1915.	2.2	6
125	Telemedicine and psoriatic arthritis: best practices and considerations for dermatologists and rheumatologists. <i>Clinical Rheumatology</i> , 2022, 41, 1271-1283.	2.2	6
126	Adaptive Clinical Trial Design: An Overview and Potential Applications in Dermatology. <i>Journal of Investigative Dermatology</i> , 2016, 136, 1325-1329.	0.7	5



#	ARTICLE	IF	CITATIONS
127	Musculoskeletal Imaging for Dermatologists: Techniques in the Diagnosis and Management of Psoriatic Arthritis. <i>Dermatology and Therapy</i> , 2021, 11, 1199-1216.	3.0	5
128	Psychometric Validation of the Psoriasis Symptoms and Impacts Measure (P-SIM): A Novel Patient-Reported Outcome Instrument for Patients with Plaque Psoriasis, Using Reported Data from the BE RADIANT Phase 3b Trial. <i>Advances in Therapy</i> , 2021, 38, 5253-5269.	2.9	5
129	Trial Characteristics as Contextual Factors When Evaluating Targeted Therapies in Patients With Psoriatic Disease: A Meta-Epidemiologic Study. <i>Arthritis Care and Research</i> , 2018, 70, 1206-1217.	3.4	4
130	Apremilast in Combination With an Interleukin 17A Inhibitor in the Treatment of Recalcitrant Palmoplantar Psoriasis. <i>Journal of Psoriasis and Psoriatic Arthritis</i> , 2018, 3, 122-125.	0.7	4
131	Signal Detection and Methodological Limitations in a Real-World Registry: Learnings from the Evaluation of Long-Term Safety Analyses in PSOLAR. <i>Drug Safety</i> , 2021, 44, 699-709.	3.2	4
132	Psychometric Validation of the Psoriasis Symptoms and Impacts Measure (P-SIM), a Novel Patient-Reported Outcome Instrument for Patients with Plaque Psoriasis, Using Data from the BEVID and BEREADY Phase 3 Trials. <i>Dermatology and Therapy</i> , 2021, 11, 1551-1569.	3.0	4
133	Simultaneous Nail and Skin Clearance in Ixekizumab Head-to-Head Trials for Moderate-to-Severe Psoriasis and Psoriatic Arthritis. <i>Dermatology and Therapy</i> , 2022, 12, 911.	3.0	4
134	Methotrexate improves pro- and anti-atherogenic genomic expression in psoriatic skin. <i>Journal of Dermatological Science</i> , 2016, 82, 207-209.	1.9	3
135	Effect of psoriatic arthritis on ixekizumab clinical outcomes in moderate-to-severe psoriasis patients: A post hoc analysis. <i>Journal of the American Academy of Dermatology</i> , 2018, 79, 593-595.	1.2	3
136	Secukinumab provides sustained improvements in the signs and symptoms of active psoriatic arthritis: 4-year results from the Phase 3 FUTURE 2 study. <i>Rheumatology</i> , 2019, 58, .	1.9	3
137	Discrete Papular Lichen Myxedematosus and Scleromyxedema with Hypothyroidism: A Report of Two Cases. <i>Case Reports in Dermatology</i> , 2019, 11, 64-70.	0.8	3
138	Characteristics of Patients with Psoriasis Treated with Apremilast in the Corrona Psoriasis Registry. <i>Dermatology and Therapy</i> , 2021, 11, 253-263.	3.0	3
139	Focus on psoriatic arthritis and comorbidities. <i>Expert Review of Dermatology</i> , 2008, 3, S35-S36.	0.3	2
140	Outcome Measures in Psoriasis and Psoriatic Arthritis. <i>Current Dermatology Reports</i> , 2013, 2, 159-163.	2.1	2
141	Practical Assessment of Psoriasis Clinical Severity in both Clinical Trials and Clinical Practice Settings: A Report from the GRAPPA 2016 Annual Meeting. <i>Journal of Rheumatology</i> , 2017, 44, 691-692.	2.0	2
142	Comment on "Quantitative Evaluation of Biologic Therapy Options for Psoriasis: A Systematic Review and Network Meta-Analysis". <i>Journal of Investigative Dermatology</i> , 2017, 137, 2642-2644.	0.7	2
143	Interleukin-17 Inhibition in a Patient With Psoriasis and Concurrent Vitiligo. <i>Journal of Psoriasis and Psoriatic Arthritis</i> , 2018, 3, 126-130.	0.7	2
144	Measurement properties of instruments assessing psoriatic arthritis symptoms for psoriasis clinical trials: a systematic literature review. <i>Expert Review of Clinical Immunology</i> , 2020, 16, 267-283.	3.0	2

#	ARTICLE	IF	CITATIONS
145	Low gene expression of TNF, IL17A, IL23A, and IL12B in tumors: A safety surrogate to predict cancer survival associated with biologic therapies. <i>Journal of the American Academy of Dermatology</i> , 2021, 85, 249-252.	1.2	2
146	Report of the Skin Research Workgroups from the GRAPPA 2018 Annual Meeting. <i>Journal of Rheumatology</i> , 2019, 95, 28-32.	2.0	2
147	Psoriasisform Eruption following the Treatment of Cutaneous Sarcoidosis with Infliximab. <i>Psoriasis Forum</i> , 2010, 16a, 64-66.	0.1	1
148	Psoriasis: Ustekinumab and Other Biologics in the Pipeline. <i>Current Dermatology Reports</i> , 2012, 1, 108-114.	2.1	1
149	A Review of Home Phototherapy and Available Home and Handheld Phototherapy Units. <i>Psoriasis Forum</i> , 2013, 19a, 71-75.	0.1	1
150	Analysis of Gender Differences in the Efficacy of Psoriasis Treatment Modalities Resulting in Clearance. <i>Psoriasis Forum</i> , 2015, 21a, 28-34.	0.1	1
151	Secukinumab Provides Clearer Skin and Better Control on Patient-Reported Psoriasis Symptoms of Itching, Pain, and Scaling than Placebo and Etanercept. <i>Journal of Psoriasis and Psoriatic Arthritis</i> , 2016, 1, 167-174.	0.7	1
152	Greater Efficacy with Secukinumab Treatment is Associated with Greater Psoriasis Symptom Relief: Results from Secukinumab Clinical Trial Data. <i>Journal of Psoriasis and Psoriatic Arthritis</i> , 2017, 2, 73-80.	0.7	1
153	Patient-Reported Outcomes Measures in Psoriasis. <i>Journal of Psoriasis and Psoriatic Arthritis</i> , 2017, 2, 41-46.	0.7	1
154	Patient-Reported Outcome Measures for Pediatric Psoriasis: A Systematic Review and Critical Appraisal from International Dermatology Outcome Measures (IDEOM). <i>Dermatology</i> , 2018, 234, 112-119.	2.1	1
155	AB0738...DUAL NEUTRALISATION OF INTERLEUKIN (IL) 17A AND 17F WITH BIMEKIZUMAB IN MODERATE-TO-SEVERE PLAQUE PSORIASIS: 60-WEEK RESULTS FROM A RANDOMISED, DOUBLE-BLINDED, PHASE 2B EXTENSION STUDY. , 2019, , .		1
156	Report from the International Dermatology Outcome Measures Initiative. <i>Journal of Investigative Dermatology Symposium Proceedings</i> , 2020, 20, S80-S83.	0.8	1
157	Interactive, Proof of Concept Clinical Trial Design in Hidradenitis Suppurativa. <i>Journal of Investigative Dermatology</i> , 2021, 141, 431-433.	0.7	1
158	Secukinumab demonstrates high and sustained efficacy in nail psoriasis: Post hoc analysis from phase 3 trials in patients with psoriatic arthritis. <i>British Journal of Dermatology</i> , 2022, , .	1.5	1
159	Safety and Tolerability of 60 Weeks' Extended Efalizumab Therapy in Patients with Chronic Moderate to Severe Plaque Psoriasis. <i>Psoriasis Forum</i> , 2007, 13a, 28-33.	0.1	0
160	Nail Psoriasis: A Review of Treatment. <i>Psoriasis Forum</i> , 2010, 16a, 35-43.	0.1	0
161	C-Reactive Protein and Cardiovascular Disease in Psoriasis. <i>Psoriasis Forum</i> , 2011, 17a, 24-32.	0.1	0
162	Safety Updates on Tumor Necrosis Factor Blockers. <i>Psoriasis Forum</i> , 2012, 18a, 98-109.	0.1	0

#	ARTICLE	IF	CITATIONS
163	Impact of Accountable Care Organizations on Psoriasis Care. Psoriasis Forum, 2012, 18a, 221-224.	0.1	0
164	The Therapeutic Applications of Janus Kinase Inhibition in Psoriasis. Psoriasis Forum, 2012, 18a, 118-125.	0.1	0
165	Merits of Mycophenolate Mofetil for Psoriasis: Is It Effective?. Psoriasis Forum, 2013, 19a, 176-181.	0.1	0
166	ICD-10 for the Dermatologist and Psoriasis Care Provider. Psoriasis Forum, 2014, 20a, 104-107.	0.1	0
167	The Comparative Efficacy of Traditional Systemic, Biologic, and Combination Therapies in the Treatment of Psoriasis: An Expansion Study. Journal of Psoriasis and Psoriatic Arthritis, 2015, 1, 18-26.	0.7	0
168	Effect of Pregnancy on Psoriasis and Psoriatic Arthritis. Psoriasis Forum, 2015, 21a, 12-27.	0.1	0
169	Assessment of the Use of Adrenocorticotrophic Hormone in Psoriatic Arthritis. Journal of Psoriasis and Psoriatic Arthritis, 2015, 1, 52-58.	0.7	0
170	Article Commentary: Corrona's Application in Psoriatic Disease. Journal of Psoriasis and Psoriatic Arthritis, 2016, 1, 92-95.	0.7	0
171	Patient Research Partners: Lessons Learned from OMERACT Applied to Dermatology. Journal of Psoriasis and Psoriatic Arthritis, 2017, 2, 92-96.	0.7	0
172	Efficacy and safety of certolizumab pegol over four years in psoriatic arthritis patients with and without concomitant use of DMARDs. Rheumatology, 2018, 57, .	1.9	0
173	AB0763...SAFETY OF ABATACEPT TREATMENT OVER 2 YEARS IN A PHASE III ACTIVE PSORIATIC ARTHRITIS RANDOMIZED TRIAL (ASTRAEA). , 2019, , .		0
174	P277...Assessment of disease activity using RAPID3 and evaluation of treatment effect of guselkumab in patients with PsA: results from a randomised placebo-controlled Phase 2 clinical trial. Rheumatology, 2020, 59, .	1.9	0
175	Prologue: 2020 Annual Meeting of the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA). Journal of Rheumatology, 2021, , jrheum.201666.	2.0	0
176	P191...Secukinumab demonstrates a consistent safety profile in patients with psoriasis, psoriatic arthritis and ankylosing spondylitis over long term: updated pooled safety analyses. Rheumatology, 2021, 60, .	1.9	0
177	P189...Comparison of secukinumab versus adalimumab efficacy on skin outcomes in psoriatic arthritis: 52-week results from the EXCEED study. Rheumatology, 2021, 60, .	1.9	0
178	Current biologic treatments for psoriasis. Dermatology Nursing / Dermatology Nurses' Association, 2009, 21, 259-66, 272; quiz 267.	0.1	0
179	Prologue: 2021 Annual Meeting of the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA). Journal of Rheumatology, 2022, , jrheum.211317.	2.0	0
180	Report of the Skin Research Working Groups from the GRAPPA 2021 Annual Meeting. Journal of Rheumatology, 2022, , jrheum.211328.	2.0	0